Krazati

Overview

adagrasib

KRAS inhibitor

• CYP3A4 substrate
• CYP2C9 inhibitor, moderate
• CYP2D6 inhibitor, moderate
• CYP3A4 inhibitor, strong
• P-gp inhibitor, moderate
• prolongs QT interval (known)

Contraindicated

• alfuzosin
Krazati (adagrasib)

+

alfuzosin

1 interaction

Contraindicated

adagrasib + alfuzosin

contraindicated: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• alprazolam
Krazati (adagrasib)

+

alprazolam

1 interaction

Contraindicated

adagrasib + alprazolam

contraindicated: combo may incr. alprazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• cisapride
Krazati (adagrasib)

+

cisapride

1 interaction

Contraindicated

adagrasib + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• colchicine
Krazati (adagrasib)

+

colchicine

1 interaction

Contraindicated

adagrasib + colchicine

CV RISK REDUCTION: contraindicated; GOUT or FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, use alternative or decr. colchicine dose based on indication during and x14 days after adagrasib use as follows: GOUT PROPHYLAXIS: give colchicine 0.3 mg qod-qd; ACUTE GOUT TX: avoid combo if already receiving colchicine for gout prophylaxis; otherwise, give colchicine 0.6 mg x1 only; FMF: decr. max colchicine dose to 0.6 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• conivaptan
Krazati (adagrasib)

+

conivaptan

1 interaction

Contraindicated

adagrasib + conivaptan

contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metabolism inhibited)

• deuruxolitinib
Krazati (adagrasib)

+

deuruxolitinib

1 interaction

Contraindicated

adagrasib + deuruxolitinib

contraindicated: combo may incr. deuruxolitinib levels, risk of serious infection, thromboembolism, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• dihydroergotamine
Krazati (adagrasib)

+

dihydroergotamine

1 interaction

Contraindicated

adagrasib + dihydroergotamine

contraindicated: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• domperidone
Krazati (adagrasib)

+

domperidone

1 interaction

Contraindicated

adagrasib + domperidone

contraindicated: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• dronedarone
Krazati (adagrasib)

+

dronedarone

1 interaction

Contraindicated

adagrasib + dronedarone

contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• eliglustat
Krazati (adagrasib)

+

eliglustat

1 interaction

Contraindicated

adagrasib + eliglustat

contraindicated: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• eplerenone
Krazati (adagrasib)

+

eplerenone

1 interaction

Contraindicated

adagrasib + eplerenone

contraindicated: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

• ergotamine
Krazati (adagrasib)

+

ergotamine

1 interaction

Contraindicated

adagrasib + ergotamine

contraindicated: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• finerenone
Krazati (adagrasib)

+

finerenone

1 interaction

Contraindicated

adagrasib + finerenone

contraindicated: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

• flibanserin
Krazati (adagrasib)

+

flibanserin

1 interaction

Contraindicated

adagrasib + flibanserin

contraindicated w/in 14 days prior to, during, and x2 days after flibanserin tx: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited)

• gepirone
Krazati (adagrasib)

+

gepirone

1 interaction

Contraindicated

adagrasib + gepirone

contraindicated: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• isavuconazonium
Krazati (adagrasib)

+

isavuconazonium

1 interaction

Contraindicated

adagrasib + isavuconazonium

contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ivabradine
Krazati (adagrasib)

+

ivabradine

1 interaction

Contraindicated

adagrasib + ivabradine

contraindicated: combo may incr. ivabradine levels, risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• levoketoconazole
Krazati (adagrasib)

+

levoketoconazole

1 interaction

Contraindicated

adagrasib + levoketoconazole

contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• lomitapide
Krazati (adagrasib)

+

lomitapide

1 interaction

Contraindicated

adagrasib + lomitapide

contraindicated: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• lonafarnib
Krazati (adagrasib)

+

lonafarnib

1 interaction

Contraindicated

adagrasib + lonafarnib

contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• lovastatin
Krazati (adagrasib)

+

lovastatin

1 interaction

Contraindicated

adagrasib + lovastatin

contraindicated: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• lurasidone
Krazati (adagrasib)

+

lurasidone

1 interaction

Contraindicated

adagrasib + lurasidone

contraindicated: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• naloxegol
Krazati (adagrasib)

+

naloxegol

1 interaction

Contraindicated

adagrasib + naloxegol

contraindicated: combo may incr. naloxegol levels, risk of adverse effects (hepatic metabolism inhibited)

• pacritinib
Krazati (adagrasib)

+

pacritinib

1 interaction

Contraindicated

adagrasib + pacritinib

contraindicated: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• pimozide
Krazati (adagrasib)

+

pimozide

1 interaction

Contraindicated

adagrasib + pimozide

contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• posaconazole
Krazati (adagrasib)

+

posaconazole

1 interaction

Contraindicated

adagrasib + posaconazole

contraindicated: combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• ranolazine
Krazati (adagrasib)

+

ranolazine

1 interaction

Contraindicated

adagrasib + ranolazine

contraindicated: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• silodosin
Krazati (adagrasib)

+

silodosin

1 interaction

Contraindicated

adagrasib + silodosin

contraindicated: combo may incr. silodosin levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• simvastatin
Krazati (adagrasib)

+

simvastatin

1 interaction

Contraindicated

adagrasib + simvastatin

contraindicated: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• suzetrigine
Krazati (adagrasib)

+

suzetrigine

1 interaction

Contraindicated

adagrasib + suzetrigine

contraindicated: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• thioridazine
Krazati (adagrasib)

+

thioridazine

1 interaction

Contraindicated

adagrasib + thioridazine

contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• tolvaptan
Krazati (adagrasib)

+

tolvaptan

1 interaction

Contraindicated

adagrasib + tolvaptan

contraindicated: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metabolism inhibited)

• triazolam
Krazati (adagrasib)

+

triazolam

1 interaction

Contraindicated

adagrasib + triazolam

contraindicated: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ubrogepant
Krazati (adagrasib)

+

ubrogepant

1 interaction

Contraindicated

adagrasib + ubrogepant

contraindicated: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• venetoclax
Krazati (adagrasib)

+

venetoclax

1 interaction

Contraindicated

adagrasib + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• voclosporin
Krazati (adagrasib)

+

voclosporin

1 interaction

Contraindicated

adagrasib + voclosporin

contraindicated: combo may incr. voclosporin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

Avoid/Use Alternative

• abrocitinib
Krazati (adagrasib)

+

abrocitinib

1 interaction

Avoid/Use Alternative

adagrasib + abrocitinib

avoid combo if also combined w/ moderate or strong CYP2C19 inhibitor; otherwise, caution advised: combo may incr. abrocitinib and active metabolite levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited)

• acalabrutinib
Krazati (adagrasib)

+

acalabrutinib

1 interaction

Avoid/Use Alternative

adagrasib + acalabrutinib

avoid combo or hold acalabrutinib if adagrasib tx <7 days: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ado-trastuzumab emtansine
Krazati (adagrasib)

+

ado-trastuzumab emtansine

1 interaction

Avoid/Use Alternative

adagrasib + ado-trastuzumab emtansine

avoid combo during adagrasib tx; may start/restart ado-trastuzumab emtansine after adagrasib cleared (approx. 3 inhibitor half-lives): combo may incr. small molecule cytotoxin (DM1) levels, risk of myelosuppression, hepatotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism possibly inhibited)

• alfentanil
Krazati (adagrasib)

+

alfentanil

1 interaction

Avoid/Use Alternative

adagrasib + alfentanil

use alternative or monitor respiratory rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and respiratory depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metabolism inhibited)

• almotriptan
Krazati (adagrasib)

+

almotriptan

1 interaction

Avoid/Use Alternative

adagrasib + almotriptan

limit almotriptan start dose to 6.25 mg PO x1, max 12.5 mg/24h; avoid combo if concomitant renal or hepatic impairment: combo may incr. almotriptan levels, risk of adverse effects (hepatic metabolism inhibited)

• amiodarone
Krazati (adagrasib)

+

amiodarone

1 interaction

Avoid/Use Alternative

adagrasib + amiodarone

use alternative or monitor ECG, electrolytes: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• amphetamine
Krazati (adagrasib)

+

amphetamine

1 interaction

Avoid/Use Alternative

adagrasib + amphetamine

consider alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. amphetamine start dose: combo may incr. amphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metabolism inhibited)

• anagrelide
Krazati (adagrasib)

+

anagrelide

1 interaction

Avoid/Use Alternative

adagrasib + anagrelide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apalutamide
Krazati (adagrasib)

+

apalutamide

1 interaction

Avoid/Use Alternative

adagrasib + apalutamide

avoid combo: combo may decr. adagrasib levels, efficacy; may incr. apalutamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited, additive effects)

• apixaban
Krazati (adagrasib)

+

apixaban

1 interaction

Avoid/Use Alternative

adagrasib + apixaban

ADULT PTS: monitor bleeding s/sx; decr. apixaban 5 mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• apomorphine
Krazati (adagrasib)

+

apomorphine

1 interaction

Avoid/Use Alternative

adagrasib + apomorphine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aprepitant
Krazati (adagrasib)

+

aprepitant

1 interaction

Avoid/Use Alternative

adagrasib + aprepitant

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• aripiprazole bimonthly injection
Krazati (adagrasib)

+

aripiprazole bimonthly injection

1 interaction

Avoid/Use Alternative

adagrasib + aripiprazole bimonthly injection

for concurrent use >14 days, decr. aripiprazole dose to 720 mg q2mo; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, avoid combo: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• aripiprazole lauroxil
Krazati (adagrasib)

+

aripiprazole lauroxil

1 interaction

Avoid/Use Alternative

adagrasib + aripiprazole lauroxil

ARISTADA INITIO: avoid combo; ARISTADA: if concurrent use >14 days, decr. aripiprazole lauroxil 1064 mg q2mo to 441 mg qmo, 882 mg q6wk to 441 mg qmo, 882 mg qmo to 662 mg qmo, 662 mg qmo to 441 mg qmo; if also CYP2D6 PM, decr. 1064 mg q2mo to 441 mg qmo, 882 mg qmo or q6wk to 441 mg qmo, 662 mg qmo to 441 mg qmo; if also combined w/ strong CYP2D6 inhibitor, avoid combo w/ 1064 mg, 882 mg, or 662 mg doses; no dose adjustment if on 441 mg dose: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• aripiprazole monthly injection
Krazati (adagrasib)

+

aripiprazole monthly injection

1 interaction

Avoid/Use Alternative

adagrasib + aripiprazole monthly injection

1-DAY START REGIMEN: for concurrent use >14 days, decr. IM aripiprazole 400 mg dose to 300 mg; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, avoid combo; 14-DAY START REGIMEN: for concurrent use >14 days, decr. IM aripiprazole 400 mg dose to 300 mg or decr. 300 mg dose to 200 mg; if also CYP2D6 PM, decr. IM aripiprazole dose to 200 mg; if also combined w/ strong CYP2D6 inhibitor, decr. IM aripiprazole 400 mg dose to 200 mg and decr. 300 mg dose to 160 mg: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• arsenic trioxide
Krazati (adagrasib)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

adagrasib + arsenic trioxide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Krazati (adagrasib)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

adagrasib + artemether/ lumefantrine

use alternative or monitor ECG, electrolytes: combo may incr. artemether/lumefantrine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• asenapine
Krazati (adagrasib)

+

asenapine

1 interaction

Avoid/Use Alternative

adagrasib + asenapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• atazanavir
Krazati (adagrasib)

+

atazanavir

1 interaction

Avoid/Use Alternative

adagrasib + atazanavir

avoid combo until adagrasib at steady state (approx. 8 days); otherwise, monitor bilirubin: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hyperbilirubinemia, other adverse effects (hepatic metabolism inhibited)

• avanafil
Krazati (adagrasib)

+

avanafil

1 interaction

Avoid/Use Alternative

adagrasib + avanafil

avoid combo: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• avapritinib
Krazati (adagrasib)

+

avapritinib

1 interaction

Avoid/Use Alternative

adagrasib + avapritinib

avoid combo: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• axitinib
Krazati (adagrasib)

+

axitinib

1 interaction

Avoid/Use Alternative

adagrasib + axitinib

use alternative or decr. axitinib dose approx. 50%: combo may incr. axitinib levels, risk of adverse effects (hepatic metabolism inhibited)

• azithromycin
Krazati (adagrasib)

+

azithromycin

1 interaction

Avoid/Use Alternative

adagrasib + azithromycin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Krazati (adagrasib)

+

bedaquiline

1 interaction

Avoid/Use Alternative

adagrasib + bedaquiline

use alternative or monitor ECG, electrolytes: combo may incr. bedaquiline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• bosentan
Krazati (adagrasib)

+

bosentan

1 interaction

Avoid/Use Alternative

adagrasib + bosentan

avoid combo: combo may incr. bosentan levels, risk of adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• bosutinib
Krazati (adagrasib)

+

bosutinib

1 interaction

Avoid/Use Alternative

adagrasib + bosutinib

avoid combo: combo may incr. bosutinib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• brigatinib
Krazati (adagrasib)

+

brigatinib

1 interaction

Avoid/Use Alternative

adagrasib + brigatinib

use alternative or monitor BP, HR; decr. brigatinib dose by approx. 50% as follows: if taking 180 mg, decr. to 90 mg; if taking 90 mg, decr. to 60 mg: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metabolism inhibited)

• bromocriptine
Krazati (adagrasib)

+

bromocriptine

1 interaction

Avoid/Use Alternative

adagrasib + bromocriptine

avoid combo if diabetes tx; otherwise, consider decr. bromocriptine dose: combo may incr. bromocriptine levels, risk of adverse effects (hepatic metabolism inhibited)

• budesonide
Krazati (adagrasib)

+

budesonide

1 interaction

Avoid/Use Alternative

adagrasib + budesonide

avoid combo: combo may incr. budesonide levels, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

• budesonide rectal
Krazati (adagrasib)

+

budesonide rectal

1 interaction

Avoid/Use Alternative

adagrasib + budesonide rectal

avoid combo: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

• buprenorphine
Krazati (adagrasib)

+

buprenorphine

1 interaction

Avoid/Use Alternative

adagrasib + buprenorphine

use alternative or monitor respiratory rate, ECG; consider decr. buprenorphine dose: combo may incr. buprenorphine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• buspirone
Krazati (adagrasib)

+

buspirone

1 interaction

Avoid/Use Alternative

adagrasib + buspirone

consider alternative or restart buspirone dose at 2.5 mg qd: combo may incr. buspirone levels, risk of adverse effects (hepatic metabolism inhibited)

• butalbital
Krazati (adagrasib)

+

butalbital

1 interaction

Avoid/Use Alternative

adagrasib + butalbital

avoid combo: combo may decr. adagrasib levels, efficacy (hepatic metabolism induced)

• cabazitaxel
Krazati (adagrasib)

+

cabazitaxel

1 interaction

Avoid/Use Alternative

adagrasib + cabazitaxel

use alternative or consider decr. cabazitaxel dose 25%; monitor CBC: combo may incr. cabazitaxel levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• cabozantinib
Krazati (adagrasib)

+

cabozantinib

1 interaction

Avoid/Use Alternative

adagrasib + cabozantinib

use alternative or monitor ECG, electrolytes, BP, bleeding s/sx; decr. cabozantinib daily dose by 40 mg if medullary thyroid CA use or decr. by 20 mg if renal cell CA, hepatocellular CA, differentiated thyroid CA, or NET use: combo may incr. cabozantinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• capivasertib
Krazati (adagrasib)

+

capivasertib

1 interaction

Avoid/Use Alternative

adagrasib + capivasertib

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• carbamazepine
Krazati (adagrasib)

+

carbamazepine

1 interaction

Avoid/Use Alternative

adagrasib + carbamazepine

avoid combo: combo may decr. adagrasib levels, efficacy; may incr. carbamazepine levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• cariprazine
Krazati (adagrasib)

+

cariprazine

1 interaction

Avoid/Use Alternative

adagrasib + cariprazine

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING ADAGRASIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• ceritinib
Krazati (adagrasib)

+

ceritinib

1 interaction

Avoid/Use Alternative

adagrasib + ceritinib

avoid combo until adagrasib at steady state (approx. 8 days); otherwise, use alternative or monitor ECG, electrolytes and decr. ceritinib dose 33%: combo may incr. ceritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• chloramphenicol
Krazati (adagrasib)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

adagrasib + chloramphenicol

avoid combo until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• chloroquine
Krazati (adagrasib)

+

chloroquine

1 interaction

Avoid/Use Alternative

adagrasib + chloroquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• citalopram
Krazati (adagrasib)

+

citalopram

1 interaction

Avoid/Use Alternative

adagrasib + citalopram

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clarithromycin
Krazati (adagrasib)

+

clarithromycin

1 interaction

Avoid/Use Alternative

adagrasib + clarithromycin

avoid combo until adagrasib at steady state (approx. 8 days); otherwise, use alternative or monitor ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• clofazimine
Krazati (adagrasib)

+

clofazimine

1 interaction

Avoid/Use Alternative

adagrasib + clofazimine

use alternative or monitor ECG, electrolytes: combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• cobicistat
Krazati (adagrasib)

+

cobicistat

1 interaction

Avoid/Use Alternative

adagrasib + cobicistat

avoid combo until adagrasib at steady state (approx. 8 days); otherwise, caution advised: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias (hepatic metabolism inhibited)

• cobimetinib
Krazati (adagrasib)

+

cobimetinib

1 interaction

Avoid/Use Alternative

adagrasib + cobimetinib

avoid combo: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)

• codeine
Krazati (adagrasib)

+

codeine

1 interaction

Avoid/Use Alternative

adagrasib + codeine

consider alternative: combo may incr. codeine and active metabolite morphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may decr. active metabolite morphine levels, efficacy (hepatic metabolism inhibited, may alter production of active metabolite morphine)

• copanlisib
Krazati (adagrasib)

+

copanlisib

1 interaction

Avoid/Use Alternative

adagrasib + copanlisib

use alternative or decr. copanlisib dose to 45 mg; monitor CBC: combo may incr. copanlisib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• crizotinib
Krazati (adagrasib)

+

crizotinib

1 interaction

Avoid/Use Alternative

adagrasib + crizotinib

use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• dabigatran
Krazati (adagrasib)

+

dabigatran

1 interaction

Avoid/Use Alternative

adagrasib + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)

• dabrafenib
Krazati (adagrasib)

+

dabrafenib

1 interaction

Avoid/Use Alternative

adagrasib + dabrafenib

use alternative: combo may incr. dabrafenib levels, risk of adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• daridorexant
Krazati (adagrasib)

+

daridorexant

1 interaction

Avoid/Use Alternative

adagrasib + daridorexant

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• dasatinib
Krazati (adagrasib)

+

dasatinib

1 interaction

Avoid/Use Alternative

adagrasib + dasatinib

use alternative or monitor ECG, electrolytes, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after adagrasib tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• defactinib
Krazati (adagrasib)

+

defactinib

1 interaction

Avoid/Use Alternative

adagrasib + defactinib

avoid combo: combo may incr. defactinib levels, risk of adverse effects (hepatic metabolism inhibited)

• degarelix
Krazati (adagrasib)

+

degarelix

1 interaction

Avoid/Use Alternative

adagrasib + degarelix

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Krazati (adagrasib)

+

desflurane

1 interaction

Avoid/Use Alternative

adagrasib + desflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Krazati (adagrasib)

+

desipramine

1 interaction

Avoid/Use Alternative

adagrasib + desipramine

use alternative or monitor ECG, electrolytes; consider monitoring desipramine levels: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• dexamethasone
Krazati (adagrasib)

+

dexamethasone

1 interaction

Avoid/Use Alternative

adagrasib + dexamethasone

if multiple myeloma use, use alternative or monitor hypercorticism s/sx; otherwise, caution advised: combo may incr. dexamethasone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

• dexmedetomidine
Krazati (adagrasib)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

adagrasib + dexmedetomidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Krazati (adagrasib)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

adagrasib + dexmedetomidine injection

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dextroamphetamine
Krazati (adagrasib)

+

dextroamphetamine

1 interaction

Avoid/Use Alternative

adagrasib + dextroamphetamine

consider alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. dextroamphetamine start dose: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metabolism inhibited)

• dihydrocodeine
Krazati (adagrasib)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

adagrasib + dihydrocodeine

consider alternative: combo may incr. dihydrocodeine and active metabolite dihydromorphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may decr. active metabolite dihydromorphine levels, efficacy (hepatic metabolism inhibited, may alter production of active metabolite dihydromorphine)

• disopyramide
Krazati (adagrasib)

+

disopyramide

1 interaction

Avoid/Use Alternative

adagrasib + disopyramide

use alternative or monitor disopyramide levels, ECG, electrolytes: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• docetaxel
Krazati (adagrasib)

+

docetaxel

1 interaction

Avoid/Use Alternative

adagrasib + docetaxel

use alternative or monitor CBC; consider decr. docetaxel dose 50%: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• dofetilide
Krazati (adagrasib)

+

dofetilide

1 interaction

Avoid/Use Alternative

adagrasib + dofetilide

use alternative or monitor ECG, electrolytes: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• donepezil
Krazati (adagrasib)

+

donepezil

1 interaction

Avoid/Use Alternative

adagrasib + donepezil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dordaviprone
Krazati (adagrasib)

+

dordaviprone

1 interaction

Avoid/Use Alternative

adagrasib + dordaviprone

use alternative or monitor ECG, electrolytes; separate admin.; for adult and pediatric pts weighing at least 52.5 kg, decr. dordaviprone dose to 375 mg once weekly; dose recommendation not established in pediatric pts weighing less than 52.5 kg: combo may incr. dordaviprone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• doxorubicin
Krazati (adagrasib)

+

doxorubicin

1 interaction

Avoid/Use Alternative

adagrasib + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• droperidol
Krazati (adagrasib)

+

droperidol

1 interaction

Avoid/Use Alternative

adagrasib + droperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• duvelisib
Krazati (adagrasib)

+

duvelisib

1 interaction

Avoid/Use Alternative

adagrasib + duvelisib

use alternative or decr. duvelisib dose to 15 mg; monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days): combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• efavirenz
Krazati (adagrasib)

+

efavirenz

1 interaction

Avoid/Use Alternative

adagrasib + efavirenz

consider alternative or monitor ECG, electrolytes: combo may incr. efavirenz levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• elacestrant
Krazati (adagrasib)

+

elacestrant

1 interaction

Avoid/Use Alternative

adagrasib + elacestrant

avoid combo: combo may incr. elacestrant levels, risk of adverse effects (hepatic metabolism inhibited)

• elagolix
Krazati (adagrasib)

+

elagolix

1 interaction

Avoid/Use Alternative

adagrasib + elagolix

avoid combo if elagolix 300 mg bid regimen; limit elagolix use x1mo if 200 mg bid regimen; limit elagolix use x6mo if 150 mg qd regimen: combo may incr. elagolix levels, risk of adverse effects (hepatic metabolism inhibited)

• elbasvir
Krazati (adagrasib)

+

elbasvir

1 interaction

Avoid/Use Alternative

adagrasib + elbasvir

avoid combo: combo may incr. elbasvir levels, risk of adverse effects (hepatic metabolism inhibited)

• eletriptan
Krazati (adagrasib)

+

eletriptan

1 interaction

Avoid/Use Alternative

adagrasib + eletriptan

avoid combo: combo may incr. eletriptan levels, risk of adverse effects (hepatic metabolism inhibited)

• elinzanetant
Krazati (adagrasib)

+

elinzanetant

1 interaction

Avoid/Use Alternative

adagrasib + elinzanetant

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• encorafenib
Krazati (adagrasib)

+

encorafenib

1 interaction

Avoid/Use Alternative

adagrasib + encorafenib

avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• ensartinib
Krazati (adagrasib)

+

ensartinib

1 interaction

Avoid/Use Alternative

adagrasib + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metabolism possibly inhibited, P-gp-mediated transport possibly inhibited)

• entrectinib
Krazati (adagrasib)

+

entrectinib

1 interaction

Avoid/Use Alternative

adagrasib + entrectinib

avoid combo: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• enzalutamide
Krazati (adagrasib)

+

enzalutamide

1 interaction

Avoid/Use Alternative

adagrasib + enzalutamide

avoid combo: combo may decr. adagrasib levels, efficacy (hepatic metabolism induced)

• ephedra
Krazati (adagrasib)

+

ephedra

1 interaction

Avoid/Use Alternative

adagrasib + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epirubicin
Krazati (adagrasib)

+

epirubicin

1 interaction

Avoid/Use Alternative

adagrasib + epirubicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erdafitinib
Krazati (adagrasib)

+

erdafitinib

1 interaction

Avoid/Use Alternative

adagrasib + erdafitinib

use alternative or monitor phosphate: combo may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• eribulin
Krazati (adagrasib)

+

eribulin

1 interaction

Avoid/Use Alternative

adagrasib + eribulin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erlotinib
Krazati (adagrasib)

+

erlotinib

1 interaction

Avoid/Use Alternative

adagrasib + erlotinib

use alternative or consider decr. erlotinib dose by 50 mg/day decrements: combo may incr. erlotinib levels, risk of adverse effects (hepatic metabolism inhibited)

• erythromycin
Krazati (adagrasib)

+

erythromycin

1 interaction

Avoid/Use Alternative

adagrasib + erythromycin

use alternative or monitor ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• estazolam
Krazati (adagrasib)

+

estazolam

1 interaction

Avoid/Use Alternative

adagrasib + estazolam

use alternative or monitor respiratory rate; consider decr. estazolam dose: combo may incr. estazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• etoposide
Krazati (adagrasib)

+

etoposide

1 interaction

Avoid/Use Alternative

adagrasib + etoposide

use alternative or monitor CBC: combo may incr. etoposide levels, risk of serious infection, myelosuppression, other adverse effects (additive effects)

• etrasimod
Krazati (adagrasib)

+

etrasimod

1 interaction

Avoid/Use Alternative

adagrasib + etrasimod

avoid combo: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• everolimus
Krazati (adagrasib)

+

everolimus

1 interaction

Avoid/Use Alternative

adagrasib + everolimus

TRANSPLANT: use alternative or monitor everolimus levels, CBC; ALL OTHER INDICATIONS: avoid combo: combo may incr. everolimus levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• fedratinib
Krazati (adagrasib)

+

fedratinib

1 interaction

Avoid/Use Alternative

adagrasib + fedratinib

consider alternative or monitor CBC, LFTs, ECG and electrolytes until adagrasib at steady state (approx. 8 days); decr. fedratinib dose to 200 mg qd: combo may incr. level of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• fentanyl
Krazati (adagrasib)

+

fentanyl

1 interaction

Avoid/Use Alternative

adagrasib + fentanyl

use alternative or monitor respiratory rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• fesoterodine
Krazati (adagrasib)

+

fesoterodine

1 interaction

Avoid/Use Alternative

adagrasib + fesoterodine

avoid combo in peds pts <35 kg; adjust max fesoterodine dose to 4 mg/day in adults and peds pts >35 kg: combo may incr. fesoterodine active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• fexinidazole
Krazati (adagrasib)

+

fexinidazole

1 interaction

Avoid/Use Alternative

adagrasib + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after adagrasib D/C; use alternative or monitor ECG, electrolytes during and x7 days after fexinidazole tx: combo may decr. adagrasib levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; hepatic metabolism inhibited, decr. conversion to active metabolites; additive effects)

• flecainide
Krazati (adagrasib)

+

flecainide

1 interaction

Avoid/Use Alternative

adagrasib + flecainide

use alternative or monitor ECG, electrolytes, flecainide levels: combo may incr. flecainide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• fluconazole
Krazati (adagrasib)

+

fluconazole

1 interaction

Avoid/Use Alternative

adagrasib + fluconazole

use alternative or monitor ECG, electrolytes: combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• fluorouracil
Krazati (adagrasib)

+

fluorouracil

1 interaction

Avoid/Use Alternative

adagrasib + fluorouracil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluoxetine
Krazati (adagrasib)

+

fluoxetine

1 interaction

Avoid/Use Alternative

adagrasib + fluoxetine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluticasone propionate
Krazati (adagrasib)

+

fluticasone propionate

1 interaction

Avoid/Use Alternative

adagrasib + fluticasone propionate

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

• fosaprepitant
Krazati (adagrasib)

+

fosaprepitant

1 interaction

Avoid/Use Alternative

adagrasib + fosaprepitant

avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metabolism inhibited)

• foscarnet
Krazati (adagrasib)

+

foscarnet

1 interaction

Avoid/Use Alternative

adagrasib + foscarnet

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosfomycin injection
Krazati (adagrasib)

+

fosfomycin injection

1 interaction

Avoid/Use Alternative

adagrasib + fosfomycin injection

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosphenytoin
Krazati (adagrasib)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

adagrasib + fosphenytoin

avoid combo: combo may decr. adagrasib levels, efficacy; may incr. phenytoin levels, risk of toxicity (hepatic metabolism induced; hepatic metabolism inhibited)

• futibatinib
Krazati (adagrasib)

+

futibatinib

1 interaction

Avoid/Use Alternative

adagrasib + futibatinib

avoid combo: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• gepotidacin
Krazati (adagrasib)

+

gepotidacin

1 interaction

Avoid/Use Alternative

adagrasib + gepotidacin

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• gilteritinib
Krazati (adagrasib)

+

gilteritinib

1 interaction

Avoid/Use Alternative

adagrasib + gilteritinib

use alternative or monitor ECG, electrolytes: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• givinostat
Krazati (adagrasib)

+

givinostat

1 interaction

Avoid/Use Alternative

adagrasib + givinostat

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glasdegib
Krazati (adagrasib)

+

glasdegib

1 interaction

Avoid/Use Alternative

adagrasib + glasdegib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. glasdegib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• goserelin
Krazati (adagrasib)

+

goserelin

1 interaction

Avoid/Use Alternative

adagrasib + goserelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• grapefruit
Krazati (adagrasib)

+

grapefruit

1 interaction

Avoid/Use Alternative

adagrasib + grapefruit

use alternative or monitor ECG, electrolytes w/ large amounts of grapefruit (>1L juice): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (GI metabolism inhibited, additive effects)

• grazoprevir
Krazati (adagrasib)

+

grazoprevir

1 interaction

Avoid/Use Alternative

adagrasib + grazoprevir

avoid combo: combo may incr. grazoprevir levels, risk of adverse effects (hepatic metabolism inhibited)

• haloperidol
Krazati (adagrasib)

+

haloperidol

1 interaction

Avoid/Use Alternative

adagrasib + haloperidol

use alternative or monitor ECG, electrolytes; consider decr. haloperidol dose: combo may incr. haloperidol levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• histrelin
Krazati (adagrasib)

+

histrelin

1 interaction

Avoid/Use Alternative

adagrasib + histrelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydrocodone
Krazati (adagrasib)

+

hydrocodone

1 interaction

Avoid/Use Alternative

adagrasib + hydrocodone

use alternative or monitor respiratory rate, ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day; consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• hydroxychloroquine
Krazati (adagrasib)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

adagrasib + hydroxychloroquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hydroxyzine
Krazati (adagrasib)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

adagrasib + hydroxyzine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibrutinib
Krazati (adagrasib)

+

ibrutinib

1 interaction

Avoid/Use Alternative

adagrasib + ibrutinib

avoid combo or hold ibrutinib if adagrasib tx <7 days: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ibutilide
Krazati (adagrasib)

+

ibutilide

1 interaction

Avoid/Use Alternative

adagrasib + ibutilide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• idelalisib
Krazati (adagrasib)

+

idelalisib

1 interaction

Avoid/Use Alternative

adagrasib + idelalisib

avoid combo until adagrasib at steady state (approx. 8 days); otherwise, use alternative or monitor LFTs, CBC, GI toxicity sx: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hepatotoxicity, serious infection, myelosuppression, GI toxicity, pneumonitis, other adverse effects (hepatic metabolism inhibited)

• iloperidone
Krazati (adagrasib)

+

iloperidone

1 interaction

Avoid/Use Alternative

adagrasib + iloperidone

use alternative or monitor ECG, electrolytes; decr. iloperidone dose 50%: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• imlunestrant
Krazati (adagrasib)

+

imlunestrant

1 interaction

Avoid/Use Alternative

adagrasib + imlunestrant

use alternative or decr. imlunestrant dose to 200 mg once daily: combo may incr. imlunestrant levels, risk of adverse effects (hepatic metabolism inhibited)

• inotuzumab ozogamicin
Krazati (adagrasib)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

adagrasib + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• irinotecan
Krazati (adagrasib)

+

irinotecan

1 interaction

Avoid/Use Alternative

adagrasib + irinotecan

use alternative or D/C adagrasib >1wk prior to irinotecan start: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (hepatic metabolism inhibited)

• isoflurane
Krazati (adagrasib)

+

isoflurane

1 interaction

Avoid/Use Alternative

adagrasib + isoflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• itraconazole
Krazati (adagrasib)

+

itraconazole

1 interaction

Avoid/Use Alternative

adagrasib + itraconazole

avoid combo until adagrasib at steady state (approx. 8 days) and x2wk after itraconazole tx; consider decr. itraconazole dose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ivacaftor
Krazati (adagrasib)

+

ivacaftor

1 interaction

Avoid/Use Alternative

adagrasib + ivacaftor

pts <6 mo: avoid combo; pts >6 mo decr. ivacaftor dose as follows: 6 mo-5 yo and 5-6.9 kg: give 25 mg 2x/wk; 6 mo-5 yo and 7-13.9 kg: give 50 mg 2x/wk; 6 mo-5 yo and >14 kg: give 75 mg 2x/wk; 6 yo and older: give 150 mg 2x/wk: combo may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• ivosidenib
Krazati (adagrasib)

+

ivosidenib

1 interaction

Avoid/Use Alternative

adagrasib + ivosidenib

avoid combo: combo may decr. adagrasib levels, efficacy; may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited, additive effects)

• ixabepilone
Krazati (adagrasib)

+

ixabepilone

1 interaction

Avoid/Use Alternative

adagrasib + ixabepilone

use alternative or monitor CBC; consider decr. ixabepilone dose to 20 mg/m^2, wait 1wk after inhibitor D/C before incr. dose: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited)

• ketoconazole
Krazati (adagrasib)

+

ketoconazole

1 interaction

Avoid/Use Alternative

adagrasib + ketoconazole

avoid combo until adagrasib at steady state (approx. 8 days) and up to 1wk after ketoconazole tx; consider decr. ketoconazole dose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lapatinib
Krazati (adagrasib)

+

lapatinib

1 interaction

Avoid/Use Alternative

adagrasib + lapatinib

use alternative or monitor ECG, electrolytes; consider decr. lapatinib dose to 500 mg/day: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• larotrectinib
Krazati (adagrasib)

+

larotrectinib

1 interaction

Avoid/Use Alternative

adagrasib + larotrectinib

use alternative or decr. larotrectinib dose 50%: combo may incr. larotrectinib levels, risk of adverse effects (hepatic metabolism inhibited)

• lefamulin
Krazati (adagrasib)

+

lefamulin

1 interaction

Avoid/Use Alternative

adagrasib + lefamulin

ORAL LEFAMULIN: avoid combo; IV LEFAMULIN: use alternative or monitor ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• lemborexant
Krazati (adagrasib)

+

lemborexant

1 interaction

Avoid/Use Alternative

adagrasib + lemborexant

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lenacapavir
Krazati (adagrasib)

+

lenacapavir

1 interaction

Avoid/Use Alternative

adagrasib + lenacapavir

avoid combo if also combined w/ UGT1A1 inhibitor; otherwise, monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may incr. lenacapavir levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• leniolisib
Krazati (adagrasib)

+

leniolisib

1 interaction

Avoid/Use Alternative

adagrasib + leniolisib

avoid combo: combo may incr. leniolisib levels, risk of adverse effects (hepatic metabolism inhibited)

• leuprolide
Krazati (adagrasib)

+

leuprolide

1 interaction

Avoid/Use Alternative

adagrasib + leuprolide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Krazati (adagrasib)

+

levofloxacin

1 interaction

Avoid/Use Alternative

adagrasib + levofloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lisdexamfetamine
Krazati (adagrasib)

+

lisdexamfetamine

1 interaction

Avoid/Use Alternative

adagrasib + lisdexamfetamine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metabolism inhibited)

• lofexidine
Krazati (adagrasib)

+

lofexidine

1 interaction

Avoid/Use Alternative

adagrasib + lofexidine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• loperamide
Krazati (adagrasib)

+

loperamide

1 interaction

Avoid/Use Alternative

adagrasib + loperamide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day or if also combined w/ CYP2C8 inhibitor: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• lopinavir/ritonavir
Krazati (adagrasib)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

adagrasib + lopinavir/ ritonavir

avoid combo until adagrasib at steady state (approx. 8 days); otherwise, use alternative or monitor ECG, electrolytes: combo may incr. or decr. adagrasib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered, additive effects)

• lorlatinib
Krazati (adagrasib)

+

lorlatinib

1 interaction

Avoid/Use Alternative

adagrasib + lorlatinib

use alternative or monitor ECG and decr. lorlatinib dose as follows: if on lorlatinib 100 mg/day decr. to 75 mg/day, if on lorlatinib 75 mg/day decr. to 50 mg/day: combo may incr. lorlatinib levels, risk of PR prolongation, cardiac arrhythmias, AV block, other adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• lumacaftor/ivacaftor
Krazati (adagrasib)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

adagrasib + lumacaftor/ ivacaftor

avoid combo: combo may decr. adagrasib levels, efficacy; may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• lurbinectedin
Krazati (adagrasib)

+

lurbinectedin

1 interaction

Avoid/Use Alternative

adagrasib + lurbinectedin

use alternative or monitor CBC; decr. lurbinectedin dose 50%: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• macimorelin
Krazati (adagrasib)

+

macimorelin

1 interaction

Avoid/Use Alternative

adagrasib + macimorelin

avoid combo, allowing sufficient washout time before diagnostic test: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• macitentan
Krazati (adagrasib)

+

macitentan

1 interaction

Avoid/Use Alternative

adagrasib + macitentan

avoid combo: combo may incr. macitentan levels, risk of adverse effects (hepatic metabolism inhibited)

• mefloquine
Krazati (adagrasib)

+

mefloquine

1 interaction

Avoid/Use Alternative

adagrasib + mefloquine

avoid combo during and x15wk after stopping mefloquine tx: combo may incr. mefloquine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• meloxicam
Krazati (adagrasib)

+

meloxicam

1 interaction

Avoid/Use Alternative

adagrasib + meloxicam

avoid combo if meloxicam given as fixed-dose combo w/ rizatriptan; otherwise, monitor bleeding s/sx; use lowest effective meloxicam dose, shortest duration of concomitant tx: combo may incr. meloxicam levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• meperidine
Krazati (adagrasib)

+

meperidine

1 interaction

Avoid/Use Alternative

adagrasib + meperidine

use alternative or monitor respiratory rate, ECG, electrolytes; consider decr. meperidine dose: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• methadone
Krazati (adagrasib)

+

methadone

1 interaction

Avoid/Use Alternative

adagrasib + methadone

use alternative or monitor respiratory rate, ECG, electrolytes; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• methylergonovine
Krazati (adagrasib)

+

methylergonovine

1 interaction

Avoid/Use Alternative

adagrasib + methylergonovine

avoid combo: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• midazolam
Krazati (adagrasib)

+

midazolam

1 interaction

Avoid/Use Alternative

adagrasib + midazolam

avoid combo if midazolam nasal use; otherwise, monitor respiratory rate, consider decr. midazolam dose: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• midostaurin
Krazati (adagrasib)

+

midostaurin

1 interaction

Avoid/Use Alternative

adagrasib + midostaurin

consider alternative or monitor ECG, electrolytes, CBC: combo may incr. midostaurin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• mifepristone
Krazati (adagrasib)

+

mifepristone

1 interaction

Avoid/Use Alternative

adagrasib + mifepristone

avoid combo until adagrasib at steady state (approx. 8 days) during and x14 days after daily mifepristone use; otherwise, use alternative or monitor ECG, electrolytes, decr. mifepristone dose as follows: if on mifepristone 1200 mg, decr. to 900 mg; if on mifepristone 900 mg, decr. to 600 mg, may titrate to max 900 mg/day; if on mifepristone 600 mg, decr. to 300 mg, may titrate to max 600 mg/day; if on mifepristone 300 mg, no dose adjustment needed; caution advised if pregnancy termination use: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• milsaperidone
Krazati (adagrasib)

+

milsaperidone

1 interaction

Avoid/Use Alternative

adagrasib + milsaperidone

use alternative or monitor ECG, electrolytes; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• mitapivat
Krazati (adagrasib)

+

mitapivat

1 interaction

Avoid/Use Alternative

adagrasib + mitapivat

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• mitotane
Krazati (adagrasib)

+

mitotane

1 interaction

Avoid/Use Alternative

adagrasib + mitotane

avoid combo: combo may decr. adagrasib levels, efficacy (hepatic metabolism induced)

• mobocertinib
Krazati (adagrasib)

+

mobocertinib

1 interaction

Avoid/Use Alternative

adagrasib + mobocertinib

avoid combo: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• moxifloxacin
Krazati (adagrasib)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

adagrasib + moxifloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nefazodone
Krazati (adagrasib)

+

nefazodone

1 interaction

Avoid/Use Alternative

adagrasib + nefazodone

avoid combo until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• nelfinavir
Krazati (adagrasib)

+

nelfinavir

1 interaction

Avoid/Use Alternative

adagrasib + nelfinavir

avoid combo until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• neratinib
Krazati (adagrasib)

+

neratinib

1 interaction

Avoid/Use Alternative

adagrasib + neratinib

avoid combo: combo may incr. neratinib levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• nilotinib
Krazati (adagrasib)

+

nilotinib

1 interaction

Avoid/Use Alternative

adagrasib + nilotinib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• nimodipine
Krazati (adagrasib)

+

nimodipine

1 interaction

Avoid/Use Alternative

adagrasib + nimodipine

use alternative or monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nirogacestat
Krazati (adagrasib)

+

nirogacestat

1 interaction

Avoid/Use Alternative

adagrasib + nirogacestat

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypophosphatemia, other adverse effects (hepatic metabolism inhibited)

• nisoldipine
Krazati (adagrasib)

+

nisoldipine

1 interaction

Avoid/Use Alternative

adagrasib + nisoldipine

use alternative or monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• olaparib
Krazati (adagrasib)

+

olaparib

1 interaction

Avoid/Use Alternative

adagrasib + olaparib

use alternative or monitor CBC; decr. olaparib dose to 100 mg bid: combo may incr. olaparib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• oliceridine
Krazati (adagrasib)

+

oliceridine

1 interaction

Avoid/Use Alternative

adagrasib + oliceridine

use alternative or monitor respiratory rate, ECG, electrolytes; consider decr. oliceridine frequency: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• omaveloxolone
Krazati (adagrasib)

+

omaveloxolone

1 interaction

Avoid/Use Alternative

adagrasib + omaveloxolone

use alternative or decr. omaveloxolone dose to 50 mg/day: combo may incr. omaveloxolone levels, risk of adverse effects (hepatic metabolism inhibited)

• ondansetron
Krazati (adagrasib)

+

ondansetron

1 interaction

Avoid/Use Alternative

adagrasib + ondansetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• orforglipron
Krazati (adagrasib)

+

orforglipron

1 interaction

Avoid/Use Alternative

adagrasib + orforglipron

avoid combo if also combined with OATP1B1 or OATP1B3 inhibitor; otherwise, adjust max orforglipron dose to 9 mg qd: combo may incr. orforglipron levels, risk of adverse effects (hepatic metabolism inhibited)

• osimertinib
Krazati (adagrasib)

+

osimertinib

1 interaction

Avoid/Use Alternative

adagrasib + osimertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ospemifene
Krazati (adagrasib)

+

ospemifene

1 interaction

Avoid/Use Alternative

adagrasib + ospemifene

avoid combo: combo may incr. ospemifene levels, risk of adverse effects (hepatic metabolism inhibited)

• oxaliplatin
Krazati (adagrasib)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

adagrasib + oxaliplatin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxycodone
Krazati (adagrasib)

+

oxycodone

1 interaction

Avoid/Use Alternative

adagrasib + oxycodone

use alternative or monitor respiratory rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ozanimod
Krazati (adagrasib)

+

ozanimod

1 interaction

Avoid/Use Alternative

adagrasib + ozanimod

consider alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palbociclib
Krazati (adagrasib)

+

palbociclib

1 interaction

Avoid/Use Alternative

adagrasib + palbociclib

use alternative or decr. palbociclib dose to 75 mg qd: combo may incr. palbociclib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• paliperidone
Krazati (adagrasib)

+

paliperidone

1 interaction

Avoid/Use Alternative

adagrasib + paliperidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Krazati (adagrasib)

+

palonosetron

1 interaction

Avoid/Use Alternative

adagrasib + palonosetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palovarotene
Krazati (adagrasib)

+

palovarotene

1 interaction

Avoid/Use Alternative

adagrasib + palovarotene

avoid combo: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

• pasireotide
Krazati (adagrasib)

+

pasireotide

1 interaction

Avoid/Use Alternative

adagrasib + pasireotide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pazopanib
Krazati (adagrasib)

+

pazopanib

1 interaction

Avoid/Use Alternative

adagrasib + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• pemigatinib
Krazati (adagrasib)

+

pemigatinib

1 interaction

Avoid/Use Alternative

adagrasib + pemigatinib

use alternative or monitor phosphate and decr. pemigatinib dose as follows: if on pemigatinib 13.5 mg qd, decr. to 9 mg qd; if on pemigatinib 9 mg qd, decr. to 4.5 mg qd: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• pentamidine
Krazati (adagrasib)

+

pentamidine

1 interaction

Avoid/Use Alternative

adagrasib + pentamidine

use alternative or monitor ECG, electrolytes; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pentobarbital
Krazati (adagrasib)

+

pentobarbital

1 interaction

Avoid/Use Alternative

adagrasib + pentobarbital

avoid combo: combo may decr. adagrasib levels, efficacy (hepatic metabolism induced)

• pexidartinib
Krazati (adagrasib)

+

pexidartinib

1 interaction

Avoid/Use Alternative

adagrasib + pexidartinib

use alternative or monitor LFTs, decr. pexidartinib dose as follows: if on pexidartinib 500 mg/day or 375 mg/day, decr. to 125 mg bid; if on pexidartinib 250 mg/day, decr. to 125 mg qd: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• phenobarbital
Krazati (adagrasib)

+

phenobarbital

1 interaction

Avoid/Use Alternative

adagrasib + phenobarbital

avoid combo: combo may incr. phenobarbital levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• phenytoin
Krazati (adagrasib)

+

phenytoin

1 interaction

Avoid/Use Alternative

adagrasib + phenytoin

avoid combo: combo may decr. adagrasib levels, efficacy; may incr. phenytoin levels, risk of toxicity (hepatic metabolism induced; hepatic metabolism inhibited)

• pimavanserin
Krazati (adagrasib)

+

pimavanserin

1 interaction

Avoid/Use Alternative

adagrasib + pimavanserin

avoid combo: combo may incr. pimavanserin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• pirfenidone
Krazati (adagrasib)

+

pirfenidone

1 interaction

Avoid/Use Alternative

adagrasib + pirfenidone

avoid combo if also combined w/ mod-strong CYP1A2 inhibitor; otherwise, caution advised: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metabolism inhibited)

• pirtobrutinib
Krazati (adagrasib)

+

pirtobrutinib

1 interaction

Avoid/Use Alternative

adagrasib + pirtobrutinib

use alternative or monitor CBC and decr. pirtobrutinib dose by 50 mg; if on pirtobrutinib 50 mg qd, hold tx during adagrasib use: combo may incr. pirtobrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• pitolisant
Krazati (adagrasib)

+

pitolisant

1 interaction

Avoid/Use Alternative

adagrasib + pitolisant

avoid combo: combo may incr. pitolisant levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• ponatinib
Krazati (adagrasib)

+

ponatinib

1 interaction

Avoid/Use Alternative

adagrasib + ponatinib

monitor CBC; if on ponatinib 45 mg/day, decr. to ponatinib 30 mg/day; if on ponatinib 30 mg/day, decr. to ponatinib 15 mg/day; if on ponatinib 15 mg/day, decr. to ponatinib 10 mg/day; if on ponatinib 10 mg/day, avoid adagrasib: combo may incr. ponatinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ponesimod
Krazati (adagrasib)

+

ponesimod

1 interaction

Avoid/Use Alternative

adagrasib + ponesimod

use alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• pralsetinib
Krazati (adagrasib)

+

pralsetinib

1 interaction

Avoid/Use Alternative

adagrasib + pralsetinib

use alternative or monitor ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd or 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• primidone
Krazati (adagrasib)

+

primidone

1 interaction

Avoid/Use Alternative

adagrasib + primidone

avoid combo: combo may decr. adagrasib levels, efficacy (hepatic metabolism induced)

• procainamide
Krazati (adagrasib)

+

procainamide

1 interaction

Avoid/Use Alternative

adagrasib + procainamide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Krazati (adagrasib)

+

propafenone

1 interaction

Avoid/Use Alternative

adagrasib + propafenone

avoid combo: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited, additive effects)

• quetiapine
Krazati (adagrasib)

+

quetiapine

1 interaction

Avoid/Use Alternative

adagrasib + quetiapine

use alternative or monitor ECG, electrolytes; decr. quetiapine to 1/6th of original dose: combo may incr. quetiapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• quinidine (antiarrhythmic)
Krazati (adagrasib)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

adagrasib + quinidine (antiarrhythmic)

use alternative or monitor ECG, electrolytes, quinidine levels: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• quinidine (CYP2D6 inhibitor)
Krazati (adagrasib)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

adagrasib + quinidine (CYP2D6 inhibitor)

use alternative or monitor ECG, electrolytes: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• quinine
Krazati (adagrasib)

+

quinine

1 interaction

Avoid/Use Alternative

adagrasib + quinine

use alternative or monitor ECG, electrolytes: combo may incr. quinine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• quizartinib
Krazati (adagrasib)

+

quizartinib

1 interaction

Avoid/Use Alternative

adagrasib + quizartinib

use alternative or monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• red yeast rice
Krazati (adagrasib)

+

red yeast rice

1 interaction

Avoid/Use Alternative

adagrasib + red yeast rice

use alternative or monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, red yeast rice contains varying amounts of lovastatin)

• regorafenib
Krazati (adagrasib)

+

regorafenib

1 interaction

Avoid/Use Alternative

adagrasib + regorafenib

avoid combo: combo may incr. regorafenib levels, risk of adverse effects (hepatic metabolism inhibited)

• relugolix
Krazati (adagrasib)

+

relugolix

1 interaction

Avoid/Use Alternative

adagrasib + relugolix

PROSTATE CANCER: may hold relugolix if adagrasib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before adagrasib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before adagrasib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• remibrutinib
Krazati (adagrasib)

+

remibrutinib

1 interaction

Avoid/Use Alternative

adagrasib + remibrutinib

avoid combo: combo may incr. remibrutinib levels, risk of adverse effects (hepatic metabolism inhibited)

• repotrectinib
Krazati (adagrasib)

+

repotrectinib

1 interaction

Avoid/Use Alternative

adagrasib + repotrectinib

avoid combo; D/C adagrasib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited, P-gp-mediated transport inhibited; hepatic metabolism induced)

• retapamulin topical
Krazati (adagrasib)

+

retapamulin topical

1 interaction

Avoid/Use Alternative

adagrasib + retapamulin topical

avoid combo in pts <24 mo; otherwise, caution advised: combo may incr. retapamulin levels, risk of adverse effects (hepatic metabolism inhibited)

• revumenib
Krazati (adagrasib)

+

revumenib

1 interaction

Avoid/Use Alternative

adagrasib + revumenib

use alternative or monitor ECG, electrolytes and adjust revumenib dose as follows: WEIGHT 40 KG OR MORE: decr. revumenib dose to 160 mg bid; WEIGHT <40 KG: decr. revumenib dose to 95 mg/m^2 bid: combo may incr. revumenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• ribociclib
Krazati (adagrasib)

+

ribociclib

1 interaction

Avoid/Use Alternative

adagrasib + ribociclib

avoid combo until adagrasib at steady state (approx. 8 days); otherwise, use alternative or monitor ECG, electrolytes, CBC; decr. ribociclib dose as follows: EARLY BREAST CA: decr. ribociclib dose to 200 mg qd; ADVANCED OR METASTATIC BREAST CA: decr. ribociclib dose to 400 mg qd: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• rifabutin
Krazati (adagrasib)

+

rifabutin

1 interaction

Avoid/Use Alternative

adagrasib + rifabutin

avoid combo: combo may decr. adagrasib levels, efficacy; may incr. rifabutin levels, risk of myelosuppression, uveitis, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• rifampin
Krazati (adagrasib)

+

rifampin

1 interaction

Avoid/Use Alternative

adagrasib + rifampin

avoid combo: combo may decr. adagrasib levels, efficacy (hepatic metabolism induced)

• rilpivirine
Krazati (adagrasib)

+

rilpivirine

1 interaction

Avoid/Use Alternative

adagrasib + rilpivirine

consider alternative or monitor ECG, electrolytes; risk may be lower w/ IM rilpivirine: combo may incr. rilpivirine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• rilzabrutinib
Krazati (adagrasib)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

adagrasib + rilzabrutinib

avoid combo if adagrasib use greater than 7 days; use alternative or hold rilzabrutinib if adagrasib use less than 7 days: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• rimegepant
Krazati (adagrasib)

+

rimegepant

1 interaction

Avoid/Use Alternative

adagrasib + rimegepant

avoid combo: combo may incr. rimegepant levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• ritonavir
Krazati (adagrasib)

+

ritonavir

1 interaction

Avoid/Use Alternative

adagrasib + ritonavir

avoid combo until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• rivaroxaban
Krazati (adagrasib)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

adagrasib + rivaroxaban

avoid combo: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• romidepsin
Krazati (adagrasib)

+

romidepsin

1 interaction

Avoid/Use Alternative

adagrasib + romidepsin

use alternative or monitor ECG, electrolytes, CBC; consider romidepsin dose adjustment: combo may incr. romidepsin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• rucaparib
Krazati (adagrasib)

+

rucaparib

1 interaction

Avoid/Use Alternative

adagrasib + rucaparib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ruxolitinib
Krazati (adagrasib)

+

ruxolitinib

1 interaction

Avoid/Use Alternative

adagrasib + ruxolitinib

monitor CBC; ACUTE OR CHRONIC GVHD: no adjustment; MYELOFIBROSIS INITIATION: decr. ruxolitinib start dose to 10 mg bid if Plt >100,000 or 5 mg qd if Plt 50,000-100,000; POLYCYTHEMIA VERA INITIATION: decr. ruxolitinib start dose to 5 mg bid; MYELOFIBROSIS AND POLYCYTHEMIA VERA ONGOING TX: decr. ruxolitinib maint. dose by 50%; avoid combo if maint. dose is 5 mg/day: combo may incr. ruxolitinib levels, risk of adverse effects (hepatic metabolism inhibited)

• ruxolitinib topical
Krazati (adagrasib)

+

ruxolitinib topical

1 interaction

Avoid/Use Alternative

adagrasib + ruxolitinib topical

avoid combo: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• salmeterol inhaled
Krazati (adagrasib)

+

salmeterol inhaled

1 interaction

Avoid/Use Alternative

adagrasib + salmeterol inhaled

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• sebetralstat
Krazati (adagrasib)

+

sebetralstat

1 interaction

Avoid/Use Alternative

adagrasib + sebetralstat

avoid combo: combo may incr. sebetralstat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• selpercatinib
Krazati (adagrasib)

+

selpercatinib

1 interaction

Avoid/Use Alternative

adagrasib + selpercatinib

use alternative or monitor ECG, electrolytes; decr. selpercatinib dose as follows: if on selpercatinib 40 mg tid, decr. to 40 mg qd; if on selpercatinib 80 mg bid, decr. to 40 mg bid; if on selpercatinib 120 mg bid, decr. to 40 mg bid; if on selpercatinib 160 mg bid, decr. to 80 mg bid: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• selumetinib
Krazati (adagrasib)

+

selumetinib

1 interaction

Avoid/Use Alternative

adagrasib + selumetinib

use alternative or monitor LVEF, CK, myopathy sx; decr. selumetinib dose as follows: if on selumetinib 25 mg/m^2 bid, decr. to 20 mg/m^2 bid; if on selumetinib 20 mg/m^2 bid, decr. to 15 mg/m^2 bid; see selumetinib pkg insert for specific dose adjustments: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• sertraline
Krazati (adagrasib)

+

sertraline

1 interaction

Avoid/Use Alternative

adagrasib + sertraline

use alternative or monitor ECG, electrolytes: combo may incr. sertraline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• sevabertinib
Krazati (adagrasib)

+

sevabertinib

1 interaction

Avoid/Use Alternative

adagrasib + sevabertinib

use alternative or decr. sevabertinib dose as follows: if on sevabertinib 20 mg bid, decr. to 10 mg bid; if on sevabertinib 10 mg bid, decr. to 10 mg qd; if on sevabertinib 10 mg qd, hold sevabertinib until adagrasib D/C: combo may incr. sevabertinib levels, risk of adverse effects (hepatic metabolism inhibited)

• sevoflurane
Krazati (adagrasib)

+

sevoflurane

1 interaction

Avoid/Use Alternative

adagrasib + sevoflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sildenafil
Krazati (adagrasib)

+

sildenafil

1 interaction

Avoid/Use Alternative

adagrasib + sildenafil

PULMONARY HTN: avoid combo; ERECTILE DYSFUNCTION: monitor BP; consider decr. sildenafil start dose to 25 mg: combo may incr. sildenafil levels, risk of hypotension (including syncope), priapism, other adverse effects (hepatic metabolism inhibited)

• siponimod
Krazati (adagrasib)

+

siponimod

1 interaction

Avoid/Use Alternative

adagrasib + siponimod

consider alternative or monitor HR, ECG, electrolytes: combo may incr. siponimod levels, risk of PR interval prolongation, AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• sirolimus
Krazati (adagrasib)

+

sirolimus

1 interaction

Avoid/Use Alternative

adagrasib + sirolimus

use alternative or monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• sirolimus albumin-bound
Krazati (adagrasib)

+

sirolimus albumin-bound

1 interaction

Avoid/Use Alternative

adagrasib + sirolimus albumin-bound

avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• solifenacin
Krazati (adagrasib)

+

solifenacin

1 interaction

Avoid/Use Alternative

adagrasib + solifenacin

use alternative or monitor ECG, electrolytes; adjust solifenacin dose as follows: pts 9-15 kg: max 2 mg/day; pts 16-45 kg: max 3 mg/day; pts 46-60 kg: max 4 mg/day; pts >60 kg or adult pts: max 5 mg/day: combo may incr. solifenacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• sonidegib
Krazati (adagrasib)

+

sonidegib

1 interaction

Avoid/Use Alternative

adagrasib + sonidegib

avoid combo: combo may incr. sonidegib levels, risk of adverse effects (hepatic metabolism inhibited)

• sorafenib
Krazati (adagrasib)

+

sorafenib

1 interaction

Avoid/Use Alternative

adagrasib + sorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotalol
Krazati (adagrasib)

+

sotalol

1 interaction

Avoid/Use Alternative

adagrasib + sotalol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sparsentan
Krazati (adagrasib)

+

sparsentan

1 interaction

Avoid/Use Alternative

adagrasib + sparsentan

avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

• St. John's wort
Krazati (adagrasib)

+

St. John's wort

1 interaction

Avoid/Use Alternative

adagrasib + St. John's wort

avoid combo: combo may decr. adagrasib levels, efficacy (hepatic metabolism induced)

• sufentanil
Krazati (adagrasib)

+

sufentanil

1 interaction

Avoid/Use Alternative

adagrasib + sufentanil

use alternative or monitor respiratory rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• sunitinib
Krazati (adagrasib)

+

sunitinib

1 interaction

Avoid/Use Alternative

adagrasib + sunitinib

use alternative or monitor ECG, electrolytes; consider decr. sunitinib to minimum dose as follows: GIST or RCC: 37.5 mg/day, 4wk on, 2wk off; PNET: 25 mg/day: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• sunvozertinib
Krazati (adagrasib)

+

sunvozertinib

1 interaction

Avoid/Use Alternative

adagrasib + sunvozertinib

use alternative or decr. sunvozertinib dose to 150 mg once daily: combo may incr. sunvozertinib levels, risk of adverse effects (hepatic metabolism inhibited)

• suvorexant
Krazati (adagrasib)

+

suvorexant

1 interaction

Avoid/Use Alternative

adagrasib + suvorexant

avoid combo: combo may incr. suvorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• tadalafil
Krazati (adagrasib)

+

tadalafil

1 interaction

Avoid/Use Alternative

adagrasib + tadalafil

PULMONARY HTN and BENIGN PROSTATIC HYPERPLASIA: avoid combo; ERECTILE DYSFUNCTION: monitor BP; adjust tadalafil max dose to 10 mg/dose q72h if prn dosing regimen, 2.5 mg/day if daily dosing regimen: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• taletrectinib
Krazati (adagrasib)

+

taletrectinib

1 interaction

Avoid/Use Alternative

adagrasib + taletrectinib

avoid combo: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• tamsulosin
Krazati (adagrasib)

+

tamsulosin

1 interaction

Avoid/Use Alternative

adagrasib + tamsulosin

avoid combo: combo may incr. tamsulosin levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

• tazemetostat
Krazati (adagrasib)

+

tazemetostat

1 interaction

Avoid/Use Alternative

adagrasib + tazemetostat

use alternative or monitor ECG, electrolytes, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• telavancin
Krazati (adagrasib)

+

telavancin

1 interaction

Avoid/Use Alternative

adagrasib + telavancin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• temsirolimus
Krazati (adagrasib)

+

temsirolimus

1 interaction

Avoid/Use Alternative

adagrasib + temsirolimus

use alternative or monitor CBC; consider decr. temsirolimus dose to 12.5 mg/wk: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• tetrabenazine
Krazati (adagrasib)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

adagrasib + tetrabenazine

use alternative or monitor ECG, electrolytes; consider decr. tetrabenazine dose: combo may incr. tetrabenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• thiotepa
Krazati (adagrasib)

+

thiotepa

1 interaction

Avoid/Use Alternative

adagrasib + thiotepa

use alternative or monitor CBC: combo may incr. thiotepa levels, risk of serious infection, myelosuppression, other adverse effects; may decr. thiotepa active metabolite levels, efficacy (hepatic metabolism inhibited, decr. metabolite formation)

• ticagrelor
Krazati (adagrasib)

+

ticagrelor

1 interaction

Avoid/Use Alternative

adagrasib + ticagrelor

avoid combo: combo may incr. ticagrelor levels, risk of dyspnea, bleeding, other adverse effects (hepatic metabolism inhibited)

• tipranavir
Krazati (adagrasib)

+

tipranavir

1 interaction

Avoid/Use Alternative

adagrasib + tipranavir

avoid combo until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• topotecan
Krazati (adagrasib)

+

topotecan

1 interaction

Avoid/Use Alternative

adagrasib + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited)

• toremifene
Krazati (adagrasib)

+

toremifene

1 interaction

Avoid/Use Alternative

adagrasib + toremifene

use alternative or monitor ECG, electrolytes: combo may incr. toremifene levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• trabectedin
Krazati (adagrasib)

+

trabectedin

1 interaction

Avoid/Use Alternative

adagrasib + trabectedin

avoid combo: combo may incr. trabectedin levels, risk of myelosuppression, cardiotoxicity, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• tramadol
Krazati (adagrasib)

+

tramadol

1 interaction

Avoid/Use Alternative

adagrasib + tramadol

consider alternative: combo may incr. tramadol and active metabolite levels, risk of CNS and respiratory depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. active metabolite levels, efficacy (hepatic metabolism inhibited, additive effects, altered active metabolite production)

• trazodone
Krazati (adagrasib)

+

trazodone

1 interaction

Avoid/Use Alternative

adagrasib + trazodone

use alternative or monitor ECG, BP, electrolytes; consider decr. trazodone dose: combo may incr. trazodone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• tretinoin
Krazati (adagrasib)

+

tretinoin

1 interaction

Avoid/Use Alternative

adagrasib + tretinoin

use alternative: combo may incr. tretinoin levels, risk of adverse effects (hepatic metabolism inhibited)

• triclabendazole
Krazati (adagrasib)

+

triclabendazole

1 interaction

Avoid/Use Alternative

adagrasib + triclabendazole

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Krazati (adagrasib)

+

trifluridine

1 interaction

Avoid/Use Alternative

adagrasib + trifluridine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triptorelin
Krazati (adagrasib)

+

triptorelin

1 interaction

Avoid/Use Alternative

adagrasib + triptorelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tucatinib
Krazati (adagrasib)

+

tucatinib

1 interaction

Avoid/Use Alternative

adagrasib + tucatinib

avoid combo until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• vandetanib
Krazati (adagrasib)

+

vandetanib

1 interaction

Avoid/Use Alternative

adagrasib + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vardenafil
Krazati (adagrasib)

+

vardenafil

1 interaction

Avoid/Use Alternative

adagrasib + vardenafil

monitor ECG, electrolytes; max vardenafil dose 2.5 mg/24h; avoid combo w/ ODT form: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited, additive effects)

• vemurafenib
Krazati (adagrasib)

+

vemurafenib

1 interaction

Avoid/Use Alternative

adagrasib + vemurafenib

use alternative or monitor ECG, electrolytes; consider decr. vemurafenib dose: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• vinblastine
Krazati (adagrasib)

+

vinblastine

1 interaction

Avoid/Use Alternative

adagrasib + vinblastine

use alternative or monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

• vincristine
Krazati (adagrasib)

+

vincristine

1 interaction

Avoid/Use Alternative

adagrasib + vincristine

avoid combo: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

• vinorelbine
Krazati (adagrasib)

+

vinorelbine

1 interaction

Avoid/Use Alternative

adagrasib + vinorelbine

use alternative or monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

• vorapaxar
Krazati (adagrasib)

+

vorapaxar

1 interaction

Avoid/Use Alternative

adagrasib + vorapaxar

avoid combo: combo may incr. vorapaxar levels, risk of adverse effects (hepatic metabolism inhibited)

• voriconazole
Krazati (adagrasib)

+

voriconazole

1 interaction

Avoid/Use Alternative

adagrasib + voriconazole

avoid combo until adagrasib at steady state (approx. 8 days); monitor ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• ziftomenib
Krazati (adagrasib)

+

ziftomenib

1 interaction

Avoid/Use Alternative

adagrasib + ziftomenib

use alternative or monitor ECG, electrolytes: combo may incr. ziftomenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• ziprasidone
Krazati (adagrasib)

+

ziprasidone

1 interaction

Avoid/Use Alternative

adagrasib + ziprasidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

• abemaciclib
Krazati (adagrasib)

+

abemaciclib

1 interaction

Monitor/Modify Tx

adagrasib + abemaciclib

decr. abemaciclib 150-200 mg bid dose to 100 mg bid; decr. abemaciclib 100 mg bid dose to 50 mg bid: combo may incr. abemaciclib levels, risk of adverse effects (hepatic metabolism inhibited)

• afatinib
Krazati (adagrasib)

+

afatinib

1 interaction

Monitor/Modify Tx

adagrasib + afatinib

decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (hepatic metabolism inhibited)

• aficamten
Krazati (adagrasib)

+

aficamten

1 interaction

Monitor/Modify Tx

adagrasib + aficamten

monitor cardiac fxn, incl. LVEF: combo may incr. aficamten levels, risk of cardiotoxicity, other adverse effects (hepatic metabolism inhibited)

• albuterol
Krazati (adagrasib)

+

albuterol

1 interaction

Monitor/Modify Tx

adagrasib + albuterol

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• albuterol inhaled
Krazati (adagrasib)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

adagrasib + albuterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aminophylline
Krazati (adagrasib)

+

aminophylline

1 interaction

Monitor/Modify Tx

adagrasib + aminophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited; aminophylline converted to theophylline)

• amisulpride
Krazati (adagrasib)

+

amisulpride

1 interaction

Monitor/Modify Tx

adagrasib + amisulpride

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amitriptyline
Krazati (adagrasib)

+

amitriptyline

1 interaction

Monitor/Modify Tx

adagrasib + amitriptyline

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amlodipine
Krazati (adagrasib)

+

amlodipine

1 interaction

Monitor/Modify Tx

adagrasib + amlodipine

monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)

• arformoterol inhaled
Krazati (adagrasib)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

adagrasib + arformoterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aripiprazole oral
Krazati (adagrasib)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

adagrasib + aripiprazole oral

consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• asciminib
Krazati (adagrasib)

+

asciminib

1 interaction

Monitor/Modify Tx

adagrasib + asciminib

if asciminib 200 mg bid, monitor CBC, ECG, electrolytes; otherwise, monitor ECG, electrolytes: combo may incr. asciminib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• atogepant
Krazati (adagrasib)

+

atogepant

1 interaction

Monitor/Modify Tx

adagrasib + atogepant

decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

• atorvastatin
Krazati (adagrasib)

+

atorvastatin

1 interaction

Monitor/Modify Tx

adagrasib + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• avacopan
Krazati (adagrasib)

+

avacopan

1 interaction

Monitor/Modify Tx

adagrasib + avacopan

decr. avacopan dose to 30 mg qd; monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days): combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• avatrombopag
Krazati (adagrasib)

+

avatrombopag

1 interaction

Monitor/Modify Tx

adagrasib + avatrombopag

CHRONIC IMMUNE THROMBOCYTOPENIA: monitor platelets, thrombosis s/sx; if avatrombopag tablet use, decr. start dose to 20 mg 3x/wk; if avatrombopag sprinkle use, decr. start dose to 10 mg 3x/wk; CHRONIC LIVER DZ: monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• berotralstat
Krazati (adagrasib)

+

berotralstat

1 interaction

Monitor/Modify Tx

adagrasib + berotralstat

monitor ECG, electrolytes: combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• bortezomib
Krazati (adagrasib)

+

bortezomib

1 interaction

Monitor/Modify Tx

adagrasib + bortezomib

monitor CBC; consider decr. bortezomib dose: combo may incr. bortezomib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• brentuximab vedotin
Krazati (adagrasib)

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

adagrasib + brentuximab vedotin

monitor CBC, LFTs: combo may incr. brentuximab vedotin levels, risk of serious infection, myelosuppression, peripheral neuropathy, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• brexpiprazole
Krazati (adagrasib)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

adagrasib + brexpiprazole

decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• butorphanol
Krazati (adagrasib)

+

butorphanol

1 interaction

Monitor/Modify Tx

adagrasib + butorphanol

monitor respiratory rate, consider decr. butorphanol dose: combo may incr. butorphanol levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• carvedilol
Krazati (adagrasib)

+

carvedilol

1 interaction

Monitor/Modify Tx

adagrasib + carvedilol

monitor BP, HR: combo may incr. carvedilol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• celecoxib
Krazati (adagrasib)

+

celecoxib

1 interaction

Monitor/Modify Tx

adagrasib + celecoxib

monitor bleeding s/sx; consider decr. celecoxib dose: combo may incr. celecoxib levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• chlordiazepoxide
Krazati (adagrasib)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

adagrasib + chlordiazepoxide

monitor respiratory rate: combo may incr. chlordiazepoxide levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• chlorpromazine
Krazati (adagrasib)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

adagrasib + chlorpromazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cilostazol
Krazati (adagrasib)

+

cilostazol

1 interaction

Monitor/Modify Tx

adagrasib + cilostazol

decr. cilostazol dose to 50 mg bid: combo may incr. cilostazol levels, risk of adverse effects (hepatic metabolism inhibited)

• cinacalcet
Krazati (adagrasib)

+

cinacalcet

1 interaction

Monitor/Modify Tx

adagrasib + cinacalcet

monitor iPTH, calcium, ECG: combo may incr. cinacalcet levels, risk of severe hypocalcemia (including life-threatening), QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metabolism inhibited)

• ciprofloxacin
Krazati (adagrasib)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

adagrasib + ciprofloxacin

monitor ECG, electrolytes: combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• clomipramine
Krazati (adagrasib)

+

clomipramine

1 interaction

Monitor/Modify Tx

adagrasib + clomipramine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clonazepam
Krazati (adagrasib)

+

clonazepam

1 interaction

Monitor/Modify Tx

adagrasib + clonazepam

monitor respiratory rate: combo may incr. clonazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• clozapine
Krazati (adagrasib)

+

clozapine

1 interaction

Monitor/Modify Tx

adagrasib + clozapine

monitor ECG, electrolytes, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• cyclosporine
Krazati (adagrasib)

+

cyclosporine

1 interaction

Monitor/Modify Tx

adagrasib + cyclosporine

monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days); monitor cyclosporine levels, renal fxn: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• danazol
Krazati (adagrasib)

+

danazol

1 interaction

Monitor/Modify Tx

adagrasib + danazol

monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• darifenacin
Krazati (adagrasib)

+

darifenacin

1 interaction

Monitor/Modify Tx

adagrasib + darifenacin

adjust max darifenacin dose to 7.5 mg/day: combo may incr. darifenacin levels, risk of adverse effects (hepatic metabolism inhibited)

• darunavir
Krazati (adagrasib)

+

darunavir

1 interaction

Monitor/Modify Tx

adagrasib + darunavir

monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days); otherwise, caution advised: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• deflazacort
Krazati (adagrasib)

+

deflazacort

1 interaction

Monitor/Modify Tx

adagrasib + deflazacort

decr. deflazacort to 1/3 usual dose: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

• deutetrabenazine
Krazati (adagrasib)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

adagrasib + deutetrabenazine

monitor ECG, electrolytes: combo may incr. deutetrabenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• diazepam
Krazati (adagrasib)

+

diazepam

1 interaction

Monitor/Modify Tx

adagrasib + diazepam

monitor respiratory rate: combo may incr. diazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• diazoxide
Krazati (adagrasib)

+

diazoxide

1 interaction

Monitor/Modify Tx

adagrasib + diazoxide

monitor glucose: combo may incr. diazoxide levels, risk of hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• diclofenac
Krazati (adagrasib)

+

diclofenac

1 interaction

Monitor/Modify Tx

adagrasib + diclofenac

monitor bleeding s/sx; use lowest effective diclofenac dose, shortest duration of concomitant tx: combo may incr. diclofenac levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• digoxin
Krazati (adagrasib)

+

digoxin

1 interaction

Monitor/Modify Tx

adagrasib + digoxin

monitor digoxin levels, HR; decr. digoxin frequency or dose by 30-50%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

• diltiazem
Krazati (adagrasib)

+

diltiazem

1 interaction

Monitor/Modify Tx

adagrasib + diltiazem

monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days); monitor BP, HR: combo may incr. levels of both drugs, risk of QT prolongation, AV block, bradycardia, other cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited)

• doxercalciferol
Krazati (adagrasib)

+

doxercalciferol

1 interaction

Monitor/Modify Tx

adagrasib + doxercalciferol

monitor efficacy: combo may decr. doxercalciferol efficacy (hepatic metabolism inhibited, decr. conversion to activated vitamin D)

• drospirenone (contraceptive)
Krazati (adagrasib)

+

drospirenone (contraceptive)

1 interaction

Monitor/Modify Tx

adagrasib + drospirenone (contraceptive)

monitor potassium: combo may incr. drospirenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

• drospirenone (hormone replacement)
Krazati (adagrasib)

+

drospirenone (hormone replacement)

1 interaction

Monitor/Modify Tx

adagrasib + drospirenone (hormone replacement)

monitor potassium: combo may incr. drospirenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

• edoxaban
Krazati (adagrasib)

+

edoxaban

1 interaction

Monitor/Modify Tx

adagrasib + edoxaban

monitor bleeding s/sx; decr. edoxaban dose to 30 mg/day in DVT/PE pts; no dose adjustment recommended in atrial fibrillation pts: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• elexacaftor/tezacaftor/ivacaftor
Krazati (adagrasib)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

adagrasib + elexacaftor/ tezacaftor/ ivacaftor

2-5 YO: decr. usual elexacaftor/tezacaftor/ivacaftor morning dose to one packet 2x/wk (3-4 days apart), no ivacaftor evening doses; 6 YO AND OLDER: decr. usual elexacaftor/tezacaftor/ivacaftor morning dose to two tablets 2x/wk (3-4 days apart), no ivacaftor evening doses: combo may incr. elexacaftor/tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• enfortumab vedotin
Krazati (adagrasib)

+

enfortumab vedotin

1 interaction

Monitor/Modify Tx

adagrasib + enfortumab vedotin

monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• escitalopram
Krazati (adagrasib)

+

escitalopram

1 interaction

Monitor/Modify Tx

adagrasib + escitalopram

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• esomeprazole
Krazati (adagrasib)

+

esomeprazole

1 interaction

Monitor/Modify Tx

adagrasib + esomeprazole

consider decr. esomeprazole dose if hypersecretory condition tx; otherwise, caution advised: combo may incr. esomeprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• estradiol (contraceptive)
Krazati (adagrasib)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

adagrasib + estradiol (contraceptive)

monitor thrombosis s/sx: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

• eszopiclone
Krazati (adagrasib)

+

eszopiclone

1 interaction

Monitor/Modify Tx

adagrasib + eszopiclone

adjust eszopiclone max dose to 2 mg/day: combo may incr. eszopiclone levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ethinyl estradiol (contraceptive)
Krazati (adagrasib)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

adagrasib + ethinyl estradiol (contraceptive)

monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

• felodipine
Krazati (adagrasib)

+

felodipine

1 interaction

Monitor/Modify Tx

adagrasib + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metabolism inhibited)

• fingolimod
Krazati (adagrasib)

+

fingolimod

1 interaction

Monitor/Modify Tx

adagrasib + fingolimod

monitor ECG, electrolytes overnight during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluvastatin
Krazati (adagrasib)

+

fluvastatin

1 interaction

Monitor/Modify Tx

adagrasib + fluvastatin

monitor CK, myopathy sx: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• formoterol inhaled
Krazati (adagrasib)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

adagrasib + formoterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosamprenavir
Krazati (adagrasib)

+

fosamprenavir

1 interaction

Monitor/Modify Tx

adagrasib + fosamprenavir

monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• fostamatinib
Krazati (adagrasib)

+

fostamatinib

1 interaction

Monitor/Modify Tx

adagrasib + fostamatinib

monitor BP, CBC, LFTs, consider decr. fostamatinib dose: combo may incr. fostamatinib active metabolite levels, risk of HTN, myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• fostemsavir
Krazati (adagrasib)

+

fostemsavir

1 interaction

Monitor/Modify Tx

adagrasib + fostemsavir

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gemtuzumab ozogamicin
Krazati (adagrasib)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

adagrasib + gemtuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glimepiride
Krazati (adagrasib)

+

glimepiride

1 interaction

Monitor/Modify Tx

adagrasib + glimepiride

monitor glucose: combo may incr. glimepiride levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• glipizide
Krazati (adagrasib)

+

glipizide

1 interaction

Monitor/Modify Tx

adagrasib + glipizide

monitor glucose: combo may incr. glipizide levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• glyburide
Krazati (adagrasib)

+

glyburide

1 interaction

Monitor/Modify Tx

adagrasib + glyburide

monitor glucose: combo may incr. glyburide levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• granisetron
Krazati (adagrasib)

+

granisetron

1 interaction

Monitor/Modify Tx

adagrasib + granisetron

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• guanfacine
Krazati (adagrasib)

+

guanfacine

1 interaction

Monitor/Modify Tx

adagrasib + guanfacine

decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of adverse effects (hepatic metabolism inhibited)

• hydrocortisone
Krazati (adagrasib)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

adagrasib + hydrocortisone

consider decr. hydrocortisone dose: combo may incr. hydrocortisone levels, risk of systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, other adverse effects (hepatic metabolism inhibited)

• ibrexafungerp
Krazati (adagrasib)

+

ibrexafungerp

1 interaction

Monitor/Modify Tx

adagrasib + ibrexafungerp

decr. ibrexafungerp dose to 150 mg q12h: combo may incr. ibrexafungerp levels, risk of adverse effects (hepatic metabolism inhibited)

• imatinib
Krazati (adagrasib)

+

imatinib

1 interaction

Monitor/Modify Tx

adagrasib + imatinib

monitor CBC, ECG, electrolytes until adagrasib at steady state (approx. 8 days): combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• imipramine
Krazati (adagrasib)

+

imipramine

1 interaction

Monitor/Modify Tx

adagrasib + imipramine

monitor imipramine levels: combo may incr. imipramine levels, risk of adverse effects (hepatic metabolism inhibited)

• isradipine
Krazati (adagrasib)

+

isradipine

1 interaction

Monitor/Modify Tx

adagrasib + isradipine

monitor BP: combo may incr. isradipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• istradefylline
Krazati (adagrasib)

+

istradefylline

1 interaction

Monitor/Modify Tx

adagrasib + istradefylline

adjust max istradefylline dose to 20 mg/day: combo may incr. istradefylline levels, risk of adverse effects (hepatic metabolism inhibited)

• lacosamide
Krazati (adagrasib)

+

lacosamide

1 interaction

Monitor/Modify Tx

adagrasib + lacosamide

monitor HR; consider decr. lacosamide dose if also renal or hepatic impairment: combo may incr. lacosamide levels, risk of bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lenvatinib
Krazati (adagrasib)

+

lenvatinib

1 interaction

Monitor/Modify Tx

adagrasib + lenvatinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• letermovir
Krazati (adagrasib)

+

letermovir

1 interaction

Monitor/Modify Tx

adagrasib + letermovir

monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• levalbuterol inhaled
Krazati (adagrasib)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

adagrasib + levalbuterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levomilnacipran
Krazati (adagrasib)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

adagrasib + levomilnacipran

adjust levomilnacipran max dose to 80 mg/day: combo may incr. levomilnacipran levels, risk of adverse effects (hepatic metabolism inhibited)

• lidocaine
Krazati (adagrasib)

+

lidocaine

1 interaction

Monitor/Modify Tx

adagrasib + lidocaine

monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited)

• lumateperone
Krazati (adagrasib)

+

lumateperone

1 interaction

Monitor/Modify Tx

adagrasib + lumateperone

monitor ECG, electrolytes; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• maraviroc
Krazati (adagrasib)

+

maraviroc

1 interaction

Monitor/Modify Tx

adagrasib + maraviroc

ADULTS: adjust maraviroc dose to 150 mg bid, even if also combined w/ potent CYP3A4 inducer; PEDS: see maraviroc pkg insert for age/wt-based dose adjustments: combo may incr. maraviroc levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• mavacamten
Krazati (adagrasib)

+

mavacamten

1 interaction

Monitor/Modify Tx

adagrasib + mavacamten

monitor cardiac fxn, incl. LVEF; if patient stable on adagrasib tx, initiate mavacamten at 2.5 mg qd; if adding short-term (<1wk) adagrasib tx to existing mavacamten tx, hold mavacamten until adagrasib D/C; if adding longer-term (>1wk) adagrasib tx, decr. mavacamten dose as follows for at least 12wk: decr. mavacamten 15 mg qd to 10 mg qd; decr. mavacamten 10 mg qd to 5 mg qd; decr. mavacamten 5 mg qd to 2.5 mg qd; do not start adagrasib tx if on mavacamten 2.5 mg qd: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• mavorixafor
Krazati (adagrasib)

+

mavorixafor

1 interaction

Monitor/Modify Tx

adagrasib + mavorixafor

decr. mavorixafor dose to 200 mg qd; monitor ECG, electrolytes: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• methylprednisolone
Krazati (adagrasib)

+

methylprednisolone

1 interaction

Monitor/Modify Tx

adagrasib + methylprednisolone

consider decr. methylprednisolone dose: combo may incr. methylprednisolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

• metoprolol
Krazati (adagrasib)

+

metoprolol

1 interaction

Monitor/Modify Tx

adagrasib + metoprolol

monitor BP, HR; consider lower metoprolol dose: combo may incr. metoprolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

• metronidazole
Krazati (adagrasib)

+

metronidazole

1 interaction

Monitor/Modify Tx

adagrasib + metronidazole

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mirtazapine
Krazati (adagrasib)

+

mirtazapine

1 interaction

Monitor/Modify Tx

adagrasib + mirtazapine

monitor ECG, electrolytes: combo may incr. mirtazapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• morphine
Krazati (adagrasib)

+

morphine

1 interaction

Monitor/Modify Tx

adagrasib + morphine

monitor respiratory rate, consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

• nateglinide
Krazati (adagrasib)

+

nateglinide

1 interaction

Monitor/Modify Tx

adagrasib + nateglinide

monitor glucose: combo may incr. nateglinide levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• nebivolol
Krazati (adagrasib)

+

nebivolol

1 interaction

Monitor/Modify Tx

adagrasib + nebivolol

monitor BP, HR: combo may incr. nebivolol levels, risk of hypotension, bradycardia, other adverse effects (hepatic metabolism inhibited)

• nerandomilast
Krazati (adagrasib)

+

nerandomilast

1 interaction

Monitor/Modify Tx

adagrasib + nerandomilast

decr. nerandomilast dose to 9 mg twice daily: combo may incr. nerandomilast levels, risk of adverse effects (hepatic metabolism inhibited)

• netupitant
Krazati (adagrasib)

+

netupitant

1 interaction

Monitor/Modify Tx

adagrasib + netupitant

monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• nicardipine
Krazati (adagrasib)

+

nicardipine

1 interaction

Monitor/Modify Tx

adagrasib + nicardipine

monitor BP: combo may incr. nicardipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nifedipine
Krazati (adagrasib)

+

nifedipine

1 interaction

Monitor/Modify Tx

adagrasib + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nintedanib
Krazati (adagrasib)

+

nintedanib

1 interaction

Monitor/Modify Tx

adagrasib + nintedanib

consider decr. nintedanib dose: combo may incr. nintedanib levels, risk of adverse effects (hepatic metabolism inhibited)

• nortriptyline
Krazati (adagrasib)

+

nortriptyline

1 interaction

Monitor/Modify Tx

adagrasib + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

• ofloxacin
Krazati (adagrasib)

+

ofloxacin

1 interaction

Monitor/Modify Tx

adagrasib + ofloxacin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olodaterol inhaled
Krazati (adagrasib)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

adagrasib + olodaterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• omeprazole
Krazati (adagrasib)

+

omeprazole

1 interaction

Monitor/Modify Tx

adagrasib + omeprazole

consider decr. omeprazole dose if hypersecretory condition tx; otherwise, caution advised: combo may incr. omeprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• osilodrostat
Krazati (adagrasib)

+

osilodrostat

1 interaction

Monitor/Modify Tx

adagrasib + osilodrostat

monitor ECG, electrolytes; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• paclitaxel
Krazati (adagrasib)

+

paclitaxel

1 interaction

Monitor/Modify Tx

adagrasib + paclitaxel

monitor CBC: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• paricalcitol
Krazati (adagrasib)

+

paricalcitol

1 interaction

Monitor/Modify Tx

adagrasib + paricalcitol

monitor calcium, iPTH, adjust paricalcitol dose: combo may incr. paricalcitol levels, risk of hypercalcemia, other adverse effects (hepatic metabolism inhibited)

• perphenazine
Krazati (adagrasib)

+

perphenazine

1 interaction

Monitor/Modify Tx

adagrasib + perphenazine

consider decr. perphenazine dose: combo may incr. perphenazine levels, risk of adverse effects (hepatic metabolism inhibited)

• pitavastatin
Krazati (adagrasib)

+

pitavastatin

1 interaction

Monitor/Modify Tx

adagrasib + pitavastatin

monitor CK, myopathy sx: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (P-gp-mediated transport inhibited)

• polatuzumab vedotin
Krazati (adagrasib)

+

polatuzumab vedotin

1 interaction

Monitor/Modify Tx

adagrasib + polatuzumab vedotin

monitor CBC, LFTs: combo may incr. polatuzumab vedotin levels, risk of serious infection, myelosuppression, peripheral neuropathy, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• primaquine
Krazati (adagrasib)

+

primaquine

1 interaction

Monitor/Modify Tx

adagrasib + primaquine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• promethazine
Krazati (adagrasib)

+

promethazine

1 interaction

Monitor/Modify Tx

adagrasib + promethazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propranolol
Krazati (adagrasib)

+

propranolol

1 interaction

Monitor/Modify Tx

adagrasib + propranolol

monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

• repaglinide
Krazati (adagrasib)

+

repaglinide

1 interaction

Monitor/Modify Tx

adagrasib + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• riociguat
Krazati (adagrasib)

+

riociguat

1 interaction

Monitor/Modify Tx

adagrasib + riociguat

consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• sacituzumab govitecan
Krazati (adagrasib)

+

sacituzumab govitecan

1 interaction

Monitor/Modify Tx

adagrasib + sacituzumab govitecan

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• saxagliptin
Krazati (adagrasib)

+

saxagliptin

1 interaction

Monitor/Modify Tx

adagrasib + saxagliptin

monitor glucose; adjust max saxagliptin dose to 2.5 mg/day: combo may incr. saxagliptin levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• tacrolimus
Krazati (adagrasib)

+

tacrolimus

1 interaction

Monitor/Modify Tx

adagrasib + tacrolimus

monitor tacrolimus levels, ECG, electrolytes, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• talazoparib
Krazati (adagrasib)

+

talazoparib

1 interaction

Monitor/Modify Tx

adagrasib + talazoparib

monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

• tenofovir alafenamide
Krazati (adagrasib)

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

adagrasib + tenofovir alafenamide

if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

• tenofovir disoproxil
Krazati (adagrasib)

+

tenofovir disoproxil

1 interaction

Monitor/Modify Tx

adagrasib + tenofovir disoproxil

monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

• terbutaline
Krazati (adagrasib)

+

terbutaline

1 interaction

Monitor/Modify Tx

adagrasib + terbutaline

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tezacaftor/ivacaftor
Krazati (adagrasib)

+

tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

adagrasib + tezacaftor/ ivacaftor

decr. tezacaftor/ivacaftor morning dose to 2x/wk (3-4 days apart), no ivacaftor evening doses: combo may incr. tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• theophylline
Krazati (adagrasib)

+

theophylline

1 interaction

Monitor/Modify Tx

adagrasib + theophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited)

• tofacitinib
Krazati (adagrasib)

+

tofacitinib

1 interaction

Monitor/Modify Tx

adagrasib + tofacitinib

ALL USES: monitor CBC; ADULT RHEUMATOID or PSORIATIC ARTHRITIS or ANKYLOSING SPONDYLITIS: decr. tofacitinib dose to 5 mg qd; ADULT ULCERATIVE COLITIS: decr. tofacitinib induction to 5 mg tablet bid or 11 mg XR tablet qd for up to 16 wks, then 5 mg tablet qd maintenance; do not use XR tablet for maintenance; PEDIATRIC PSORIATIC ARTHRITIS, POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: decr. usual tofacitinib bid dose to qd: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• tolterodine
Krazati (adagrasib)

+

tolterodine

1 interaction

Monitor/Modify Tx

adagrasib + tolterodine

monitor ECG, electrolytes; adjust tolterodine dose to max 2 mg/day: combo may incr. tolterodine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• torsemide
Krazati (adagrasib)

+

torsemide

1 interaction

Monitor/Modify Tx

adagrasib + torsemide

monitor renal fxn, BP: combo may incr. torsemide levels, risk of nephrotoxicity, hypotension, other adverse effects (hepatic metabolism inhibited)

• trimipramine
Krazati (adagrasib)

+

trimipramine

1 interaction

Monitor/Modify Tx

adagrasib + trimipramine

consider decr. trimipramine dose: combo may incr. trimipramine levels, risk of adverse effects (hepatic metabolism inhibited)

• upadacitinib
Krazati (adagrasib)

+

upadacitinib

1 interaction

Monitor/Modify Tx

adagrasib + upadacitinib

monitor CBC; ATOPIC DERMATITIS: limit upadacitinib dose to 15 mg qd; CROHN DZ: limit upadacitinib induction dose to 30 mg qd x12wk, followed by 15 mg qd maintenance; ULCERATIVE COLITIS: limit upadacitinib induction dose to 30 mg qd x8wk, followed by 15 mg qd maintenance; ALL OTHER INDICATIONS: no dose adjustment: combo may incr. upadacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• valbenazine
Krazati (adagrasib)

+

valbenazine

1 interaction

Monitor/Modify Tx

adagrasib + valbenazine

monitor ECG, electrolytes; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• vamorolone
Krazati (adagrasib)

+

vamorolone

1 interaction

Monitor/Modify Tx

adagrasib + vamorolone

decr. vamorolone dose to 4 mg/kg qd, up to max 200 mg/day for pts >50kg: combo may incr. vamorolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

• vanzacaftor/tezacaftor/deutivacaftor
Krazati (adagrasib)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Monitor/Modify Tx

adagrasib + vanzacaftor/ tezacaftor/ deutivacaftor

6-11 YO AND WT <40 KG: decr. vanzacaftor/tezacaftor/deutivacaftor dose to two tablets (4 mg/20 mg/50 mg each) qwk; 6-11 YO AND WT 40 KG AND ABOVE: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qwk; 12 YO AND OLDER: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qwk: combo may incr. vanzacaftor/tezacaftor/deutivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• venlafaxine
Krazati (adagrasib)

+

venlafaxine

1 interaction

Monitor/Modify Tx

adagrasib + venlafaxine

monitor ECG, electrolytes: combo may incr. venlafaxine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• verapamil
Krazati (adagrasib)

+

verapamil

1 interaction

Monitor/Modify Tx

adagrasib + verapamil

monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days); monitor BP, HR: combo may incr. levels of both drugs, risk of QT prolongation, AV block, bradycardia, other cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited)

• vilanterol inhaled
Krazati (adagrasib)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

adagrasib + vilanterol inhaled

monitor ECG, BP, HR: combo may incr. vilanterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• vilazodone
Krazati (adagrasib)

+

vilazodone

1 interaction

Monitor/Modify Tx

adagrasib + vilazodone

adjust max vilazodone dose to 20 mg/day: combo may incr. vilazodone levels, risk of adverse effects (hepatic metabolism inhibited)

• warfarin
Krazati (adagrasib)

+

warfarin

1 interaction

Monitor/Modify Tx

adagrasib + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• yohimbe
Krazati (adagrasib)

+

yohimbe

1 interaction

Monitor/Modify Tx

adagrasib + yohimbe

monitor BP, HR: combo may incr. yohimbe levels, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• zanubrutinib
Krazati (adagrasib)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

adagrasib + zanubrutinib

decr. zanubrutinib dose to 80 mg qd; monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• zolpidem
Krazati (adagrasib)

+

zolpidem

1 interaction

Monitor/Modify Tx

adagrasib + zolpidem

consider decr. zolpidem dose: combo may incr. zolpidem levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• zuranolone
Krazati (adagrasib)

+

zuranolone

1 interaction

Monitor/Modify Tx

adagrasib + zuranolone

decr. zuranolone dose to 30 mg qd: combo may incr. zuranolone levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)